Use of oral polio vaccine and the incidence of COVID-19 in the world

Background Several live attenuated vaccines were shown to provide temporary protection against a variety of infectious diseases through stimulation of the host innate immune system. Objective To test the hypothesis that countries using oral polio vaccine (OPV) have a lower cumulative number of cases diagnosed with COVID-19 per 100,000 population (CP100K) compared with those using only inactivated polio vaccine (IPV). Methods In an ecological study, the CP100K was compared between countries using OPV vs IPV. We used a random-effect meta-analysis technique to estimate the pooled mean for CP100K. We also used negative binomial regression with CP100K as the dependent variable and the human development index (HDI) and the type of vaccine used as independent variables. Results The pooled estimated mean CP100K was 4970 (95% CI 4030 to 5900) cases per 100,000 population for countries using IPV, significantly (p<0.001) higher than that for countries using OPV—1580 (1190 to 1960). Countries with higher HDI prefer to use IPV; those with lower HDI commonly use OPV. Both HDI and the type of vaccine were independent predictors of CP100K. Use of OPV compared to IPV could independently decrease the CP100K by an average of 30% at the mean HDI of 0.72. Conclusions Countries using OPV have a lower incidence of COVID-19 compared to those using IPV. This might suggest that OPV may either prevent SARS-CoV-2 infection at individual level or slow down the transmission at the community level.

[1]  M. Sajadi,et al.  COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine , 2021, JAMA network open.

[2]  Michael J. Ryan,et al.  SARS-CoV-2 Variants and Vaccines , 2021, The New England journal of medicine.

[3]  Guilin Wang,et al.  Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics , 2021, The Journal of experimental medicine.

[4]  M. Netea,et al.  Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics , 2021, Proceedings of the National Academy of Sciences.

[5]  M. Bin-Jumah,et al.  Correlation between polio immunization coverage and overall morbidity and mortality for COVID-19: an epidemiological study , 2021, Environmental Science and Pollution Research.

[6]  Fred N. Kiwanuka,et al.  BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial , 2021, The Lancet. Infectious diseases.

[7]  J. Schultze,et al.  COVID-19 and the human innate immune system , 2021, Cell.

[8]  R. A. Mir,et al.  Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma , 2020, bioRxiv.

[9]  John O. Konz,et al.  Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials , 2020, The Lancet.

[10]  P. Aaby,et al.  Can existing live vaccines prevent COVID-19? , 2020, Science.

[11]  F. Miralles-Wilhelm,et al.  Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19) , 2020, JAMA network open.

[12]  M. Netea,et al.  Non-specific effects of BCG vaccine on viral infections. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  P. Aaby,et al.  Beneficial Nonspecific Effects of Oral Polio Vaccine (OPV): Implications for the Cessation of OPV? , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Haque,et al.  Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Sterne,et al.  Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review , 2016, British Medical Journal.

[16]  R. Xavier,et al.  Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity , 2014, Science.

[17]  R. Xavier,et al.  Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes , 2012, Proceedings of the National Academy of Sciences.

[18]  Aman Verma,et al.  The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices , 2011, PLoS medicine.

[19]  H. Whittle,et al.  Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries , 1995, BMJ.

[20]  J. Melnick,et al.  Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. , 1967, American journal of epidemiology.

[21]  A. A. Smorodintsev,et al.  [Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases]. , 1992, Zhurnal mikrobiologii, epidemiologii, i immunobiologii.

[22]  M. Voroshilova.  Potential use of nonpathogenic enteroviruses for control of human disease. , 1989, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.